1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that
typically manifests clinically as an isolated amnestic deficit and progresses to
a characteristic dementia syndrome (Teipel et al., 2015). According to the
classical amyloid hypothesis, the aggregation of amyloid- (A)
into insoluble -sheet fibrils initiates the pathological cascade of AD
(De Strooper and Karran, 2016). Oligomers of the A1-42 protein are
responsible for the development and progression of AD (Masters et al., 2015).
Therefore, seeking and investigating the underlying cause that induces
A1-42 oligomer production may be important in delaying the
neurodegenerative progress of AD.
Recently, numerous studies indicated that bacteria could be a primary trigger
point by inducing abundant cerebral production and deposition of A. The
study revealed that many bacteria exist in the brains of AD patients (Fulop et al., 2018): Porphyromonas gingivalis colonized in the brains of BALB/c
mice could promote A production (Dominy et al., 2019) and
Salmonella typhimurium bacterial infections in the brains of 5XFAD mice
resulted in accelerated A deposition (Kumar et al., 2016).
Studies have also demonstrated that the
components of bacterial biofilms, such as the lipopolysaccharide (LPS) (Choi et al., 2017; Kim et al., 2017), drive the process of senile plaque formation
(Allen and Morales, 2016; Miklossy, 2016).
N-acetylmuramyl-L-alanyl-D-isoglutamine (Muramyl dipeptide, MDP) is the smallest
essential bioactive peptidoglycan motif commonly present in all bacteria (Park et al., 2017). It is an inflammation-inducing molecule in the central nervous
system (CNS) disorders (Cheng et al., 2018; Liu et al., 2015). Moreover, it
exacerbates neuronal damage (Liu et al., 2015) and down-regulates
cognition-related receptors (Grigoriev et al., 2008). Hence, MDP might play a
pathological role in AD. The relationship between MDP and A has not been
addressed yet. Combining numerous evidence of bacterial components participating
in A production (Allen and Morales, 2016; Choi et al., 2017; Kim et al., 2017; Miklossy, 2016), we hypothesized that MDP might be involved in this
process. Therefore, defining the involvement of MDP in A1-42 oligomer
production and seeking the potential molecular mechanisms might disclose the veil
of bacteria promoting the development of AD.
The p38 mitogen-activated protein kinase
(p-38 MAPK) is a stress-activated enzyme that mediates various cellular
activities, including inflammation and apoptosis (Kheiri et al., 2018). It is
hyperactivated in the brains of AD patients and mice (Sun, 2003). Prolonged
p-38 MAPK hyperfunction leads to accelerated generation and deposition of
A, while p-38 MAPK inhibitors reduce the A
plaque load (Colié et al., 2017). A peptide is generated from
the cleavage of APP primarily by the -site APP cleaving enzyme
1 (BACE1) (Read and Suphioglu, 2019). Research has confirmed that p-38 MAPK
promotes the expression of A by increasing the level of BACE1 (Guo et al., 2011). In contrast, the blockage of p-38 MAPK is indicated to effectively
ameliorate A deposition by
decreasing the expression of BACE1 (Schnöder et al., 2016). Hence, BACE1
is the crucial enzyme in the process of A generation that is mediated by
p-38 MAPK. Moreover, data from in vitro and in vivo experiments
have verified that MDP could activate p-38 MAPK (Chen et al., 2018; Liu et al., 2015). The evidence above suggested that p-38 MAPK/BACE1 might be the missing
link in MDP-induced A production. However, the regulators involved in
MDP-induced activation of p-38 MAPK are not confirmed.
Nod-like receptors (NLRs) mainly recognize exogenous pathogen-associated
molecular patterns (PAMP) such as bacteria. NLRs participate in the pathological
mechanism of multiple CNS disorders, including AD (Faustin and Reed, 2013; Ma et al., 2013). Nucleotide-binding oligomerization domain 2 (NOD2) is a member
of the NLRs and functions as a specific intracellular recognition receptor for
MDP (Al Nabhani et al., 2017). Physiologically, NOD2 has much lower
expression in the brain, while its expression increases substantially after a
bacterial infection (Nakamura et al., 2014). The higher expression of NOD2
destroys the neurovascular integrity, promotes inflammatory cell infiltration in
the CNS, leads to neuronal damage and memory impairment, and eventually
contributes to cerebral injury (Chauhan et al., 2009; Liu et al., 2015; Wang et al., 2018). Numerous studies demonstrated that p-38 MAPK mediates the
proinflammatory effect of NOD2 in signaling transduction (Zhang et al., 2015). After binding with its ligands, NOD2 recruits the receptor-interacting
protein 2 (RIP2). It activates the p-38 MAPK to
stimulate a cascade of reactions such as the inflammatory response and oxidative
stress (Negroni et al., 2018). NOD2, when agitated by MDP, directly
contributes to the activation of p-38 MAPK. Therefore, it is considered the
pivotal receptor that mediates MDP-induced A production.
Based on the above evidence, we speculated the potential underlying mechanism:
MDP promotes A1-42 oligomer production via the NOD2/p-38 MAPK/BACE1
pathway. To prove this, we carried out a preliminary exploration at the animal
level. Wild type (WT) mice received an intracerebroventricular injection of
normal saline (NS) or MDP. We detected the A1-42 oligomer and
pathway-related proteins by the western blot. We further explored the mechanism
at the cellular level. We incubated SH-SY5Y cells with MDP and demonstrated that
MDP facilitates A1-42 oligomer production. Moreover, we pretreated
SH-SY5Y cells with siRNA NOD2 or SB203580 to test the role of NOD2 and p-38 MAPK
in A1-42 oligomer generation, respectively. Thus, this research aims to
examine the involvement of MDP in A1-42 oligomer production and
elucidate the underlying mechanism.
2. Materials and methods
2.1 Animals
Animals were 28-week-old male wild type (WT) mice. They were
purchased from GemPharmatech Company (Nanjing, P. R. China). The mice were
pair-housed in standard cages with food and water. The colony room temperature
was maintained at 25 1 C on a 12-hour light/dark cycle. After two
weeks of acclimatization, the mice were randomly divided into two groups: (1) WT
mice were injected stereotactically with 1.0 l of normal saline (NS) and
(2) WT mice were injected stereotactically with 1.0 l of MDP (10
g/l). The mice were exposed to NS or MDP for four weeks. They were
then killed after aesthesia to samples. All experiments were conducted in
accordance with the National Research Council’s guide for the care and use of
laboratory animals. All efforts were made to minimize the number of animals used
and their suffering. The Animal Ethics Committee approved this study of the
Department of Laboratory Animal Science of Fudan University (Approval No:
201902006S).
2.2 Reagents and antibodies
Muramyl dipeptide was purchased from InvivoGen (San Diego, CA, USA), while the
rabbit anti-NOD2 antibody was purchased from Sigma (CA, USA). The mouse
anti-phospho-p38 MAPK and anti--actin primary antibodies were purchased
from Cell Signaling Technology (MA, USA). The rabbit anti-p-38 MAPK and
anti-BACE1 antibodies were purchased from Proteintech (Chicago, USA). The rabbit
anti-A1-42 antibody was purchased from Abcam (Cambridge, UK). The goat
anti-rabbit and anti-mouse secondary antibodies were purchased from Cell
Signaling Technology (MA, USA). SB203580, an inhibitor of the p-38 MAPK pathway,
was purchased from Cell Signaling Technology (MA, USA).
2.3 Cell culture and treatments
The SH-SY5Y cells were kindly donated by the State Key Laboratory of Medical
Neurobiology, Fudan University (Shanghai, P. R. China). The SH-SY5Y cells were
cultured in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA)
and were supplemented with 10% fetal bovine serum (Invitrogen), 100 U/mL
penicillin, and 100 M streptomycin (Invitrogen) at 37 C in a
humidified atmosphere containing 5% CO. Cells were subcultured every 2-3
days. For experiments, the cells were grown to 70-80% confluence, and the media
were replaced with Opti-MEM (Invitrogen).
2.4 Preparation of MDP
MDP was prepared as described. Briefly, the lyophilized powder of MDP was
dissolved in endotoxin-free water at a concentration of 10 mg/ml and stored at
-20 C. Before use, this MDP solution was diluted to concentrations of 5
g/ml, 10 g/ml, and 20 g/ml in cold Opti-MEM media.
2.5 Immunofluorescence staining
For immunofluorescence staining, 30-50% confluent SH-SY5Y cells
were seeded on coverslips before various treatments were applied, as described
below. Cells were washed with PBS and underwent fixation with 4%
paraformaldehyde for 20 minutes at room temperature. After that, blocking was
performed with the Blocking Buffer for Immunol Staining (Beyotime Biotechnology,
Shanghai, P. R. China) for 1 h. The cells were then incubated overnight with the
primary antibody anti-A1-42 (1: 100) at 4 C and goat
anti-rabbit IgG 488-conjugated secondary antibody for 1 h. The nuclei were
stained with DAPI for 5 minutes. All samples were assessed using the Laser
Scanning Confocal Microscopy (LEICA TCS SP8, Germany).
2.6 Knockdown of NOD2 with siRNA
NOD2 small interfering RNAs (siRNA: sense 5’-GCCUGAUGUUGGUCAAGAATT-3’ and
antisense 5’-UUCUUGACCAACAUCAGGCCA-3’) were synthesized by Hippo Biotechnology.
Cells were grown to 30-40% confluency and then transfected with Lipofectamine
RNAiMAX (Invitrogen) and siRNA according to the manufacturer’s instructions.
RT-PCR was utilized to verify the silencing efficiency after 48 h of siRNA
transfection.
2.7 Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated from cultured SH-SY5Y cells by using the TRIzol reagent,
and a ReverTra Ace qPCR RT kit (Toyobo Co., Ltd., Osaka, Japan) was used to
obtain cDNA. Quantitative real-time PCR (qRT-PCR) was performed using the SYBR
Green RT-PCR Master Mix kit (Toyobo Co., Ltd., Osaka, Japan) according to the
manufacturer’s protocol and then amplified with the real-time PCR detection
system (Eppendorf AG, Hamburg, Germany). Amplification conditions were set as
40-cycles program (95 C for 15 s, 60 C for 30 s, and 72
C for 45 s). The mRNA level of the target gene described below was
normalized to that of -actin, and the results were analyzed using the
2 method (Livak and Schmittgen, 2001). Sequences of the upstream
and downstream PCR primers to detect NOD2 mRNA used in qRT-PCR were 5-TGT
GCG GAC TCT ACT CTT-3 and 5- GTG AAC CTG AAC TTG AAC TC-3,
respectively. Sequences of the upstream and downstream PCR primers to detect
BACE1 mRNA were 5-TCT GTC GGA GGG AGC ATG AT-3 and 5- CCA CGG AAA
CTT TGT AAT GA -3, respectively. Sequences of the upstream and downstream
PCR primers to detect -actin were 5-GTG GAC ATC CGC AAA GAC-3
and 5-TAG AAA GGG TGT AAC GCA ACT A-3, respectively.
2.8 Western blot analysis
The SH-SY5Y cells and the hippocampus tissues of the WT mice were collected and
lysed in the loading buffer. The protein suspensions were collected, and a BCA
kit determined the protein concentration. The lysates were then evaluated for
protein expression using the western blot. After denaturation, equal amounts of
proteins were loaded on a 10% SDS-polyacrylamide gel. Proteins were separated by
gel electrophoresis under a constant voltage of 100 V before being transferred to
the nitrocellulose membrane (Millipore, USA). After getting blocked at room
temperature, proteins on the membrane were incubated with primary antibodies.
After washing, the membranes were further incubated with secondary antibodies for
1 h. Western blot bands were captured using the Gel Imaging System (BIO-RAD,
USA).
2.9 Statistics
All results are expressed as the Mean SD. Statistical analysis was
performed using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA).
All experiments were repeated independently three times. Statistical significance
of the difference among different groups was analyzed by one-way ANOVA or the
Student’s t-test. A value of 0.05 was considered statistically
significant.
3. Results
3.1 MDP upregulated the expressions of A1-42 oligomer, NOD2,
p-p38 MAPK, and BACE1 in the WT mice
As mentioned earlier, the NOD2/p-38
MAPK/BACE1 pathway was related to the MDP-induced A1-42 oligomer
production. Hence, the pathway-related proteins were detected (Fig. 1A). As
seen in Fig. 1A and 1B, the WT mice, subjected to a 10 g/l
injection of MDP, exhibited a higher expression of the hippocampal A1-42
oligomer. Further, the WT mice injected with MDP also exhibited higher
expressions of NOD2, p-p38 MAPK, and BACE1 (Fig. 1B). Thus, these results
suggested that MDP upregulated the expressions of A1-42 oligomer, NOD2,
p-p38 MAPK, and BACE1 in the WT mice.
Fig. 1.
MDP upregulates the expressions of A1-42
oligomer, NOD2, p-p38 MAPK, and BACE1 in WT mice. (A) The effect of MDP (10
g/l) on the upregulation of hippocampal NOD2, p-p38 MAPK, BACE1,
and A1-42 oligomer. (B) The corresponding bar graphs showing the
quantification of the respective molecules in (A). Results are expressed as the
mean SEM from at least three separate experiments.Note. versus NS: P 0.01, versus NS: P
0.001.
3.2 MDP upregulated the expressions of A1-42 oligomer, NOD2, p-p38 MAPK, and BACE1 in the SH-SY5Y cells
The pathway was further explored at the cellular level by employing the SH-SY5Y
cell line. The concentration gradient and time gradient were set up for MDP.
Results from the western blot (Fig. 2A) showed that MDP upregulated the
expression of A1-42 oligomer in a dose-dependent manner after incubation
with the SH-SY5Y cells for 24 h (Fig. 2B). It was noticed that when SH-SY5Y
cells were treated with 5 g/ml MDP, the expression level of A1-42
oligomer was upregulated, but this increase was not statistically significant
(Fig. 2B). Meanwhile, the incubation of the SH-SY5Y cells with 10 g/ml
MDP (Fig. 2C) resulted in an increase in the expression of the A1-42
oligomer in a time-dependent manner (Fig. 2D). These results suggested that
MDP promoted A1-42 oligomer production in the SH-SY5Y cells.
The pathway-related proteins were then detected. Results from the western blot
(Fig. 2A and 2C) showed that MDP upregulated the expressions of NOD2,
p-p38 MAPK, and BACE1 in a dose- and time-dependent manner (Fig. 2B and
2D). Moreover, results from qRT-PCR showed that MDP also upregulated the mRNA
level of NOD2 and BACE1 in a dose- and time-dependent manner (Fig. 2E and
2F).
These data from in vivo and in vitro experiments suggested
that the MDP-induced A1-42 oligomer production might be related to the
NOD2/p-p38 MAPK/BACE1 pathway. In the next step, SB203580 and siRNA NOD2 were
employed to test the role of p-38 MAPK and NOD2 in the MDP-induced A1-42
oligomer production, respectively.
Fig. 2.
MDP upregulates the expressions of NOD2, p-p38 MAPK,
BACE1, and A1-42 oligomer in the SH-SY5Y cells at different
concentrations (5 g/ml, 10 g/ml, 20 g/ml) and at different
times (3 h, 6 h, 12 h, and 24 h). (A) The western blot determines the effect of
different concentrations of MDP on the upregulation of NOD2, p-p38 MAPK, BACE1,
and A1-42 oligomer in the SH-SY5Y cells after incubation for 24 h. (C)
The western blot detects the effect of 10 g/ml MDP on the upregulation of
NOD2, p-p38 MAPK, BACE1, and A1-42 oligomer in the SH-SY5Y cells at
different times. (B and D) are the corresponding bar graphs showing
quantification of (A) and (C), respectively. The mRNA levels of NOD2 and BACE1
are shown in (E) and (F), respectively. Results are expressed as the Mean
SEM from three separate (n = 3) experiments performed independently.Note. versus control: P 0.05, versus control:
P 0.01, versus control: P 0.001.
3.3 Inhibition of P-38 MAPK prevented MDP-induced upregulation of BACE1
and A1-42 oligomer in the SH-SY5Y cells
SB203580, an inhibitor of the p-38 MAPK pathway, was employed to determine the
engagement of p-38 MAPK in the MDP-induced upregulation of BACE1 and
A1-42 oligomer. As seen in Fig. 3A and 3B, after MDP treatment,
the ratio of p-p38 MAPK/p-38 MAPK in the SH-SY5Y cells pretreated with SB203580
was lower than that in the cells not pretreated with SB203580. Detection of the
level of BACE1 (Fig. 3A) was the next step. It was found that the SH-SY5Y
cells pre-treated with SB203580 exhibited a decrease in the BACE1 levels at both
the gene expression level (Fig. 3C) and the mRNA level (Fig. 3H).
Moreover, the level of A1-42 oligomer was also analyzed. The
anti-A1-42 antibody from Abcam (ab201060) could detect two forms of
A1-42, including the A1-42 monomer and the A1-42
oligomer. Results from the Laser Scanning Confocal Microscopy (Fig. 3F)
showed that the fluorescence intensity of A1-42 was enhanced by MDP and
was repressed by SB203580 in comparison with the intensity of the control cells
(Fig. 3G). We were considering the results from western blot (Fig. 3A)
[that the SH-SY5Y cells pre-treated with
SB203580 exhibited decreased expression of the A1-42 oligomer after
treatment with MDP, but without any change in the expression of the
A1-42 monomer (Fig. 3D-3E)], we concluded that the
A1-42 oligomers mainly caused the change in the fluorescence intensity.
These results suggested that MDP induced the upregulation of BACE1 and
A1-42 oligomer via a p-38 MAPK-dependent pathway in the SH-SY5Y cells.
Fig. 3.
SB203580 suppresses the MDP-induced upregulation of
BACE1 and A1-42 oligomer in the SH-SY5Y cells. (A) The western blot
determines the expressions of p-p38 MAPK, p-38 MAPK, BACE1, A1-42
monomer, and A1-42 oligomer. The mRNA level of BACE1 is shown in (H).
(B-E, G) are the corresponding bar graphs showing quantification of parameters in
(A) and (F), respectively. (F) A1-42 location within the cytoplasm of
SH-SY5Y cells is induced by MDP (10 g/ml) and is decreased by SB203580 (10
M). A1-42 is shown in green and DAPI in blue color. Bar =
10 m. Results are expressed as the mean SEM from at least three
separate experiments.Note. versus control: P 0.05, versus control:
P 0.01, versus control: P 0.001, versus
MDP group: P 0.05, versus MDP group: P 0.01,
versus MDP group: P 0.001.
3.4 siRNA NOD2 reversed the MDP-induced upregulation of p-p38 MAPK,
BACE1, and A1-42 oligomer in the SH-SY5Y cells
The SH-SY5Y cells were transfected with siRNA NOD2. It was seen from the results
that the silencing efficiency was higher than 70% (Fig. 4I), and the
expression of NOD2 was suppressed by siRNA (Fig. 4A-4B). The next step
was the detection of the level of the A1-42 oligomer. From the LSCM
results (Fig. 4G), it was observed that the fluorescence intensity of
A1-42 was enhanced by MDP and was repressed by siRNA (Fig. 4H).
Combining with results from the western blot (Fig. 4A) that the SH-SY5Y
cells transfected with siRNA exhibited decreased expression of A1-42
oligomer after treatment of MDP, but without any change in the expression of the
A1-42 monomer (Fig. 4E-4F). It was concluded that the
A1-42 oligomers mainly caused the change in the fluorescence intensity.
Thus, NOD2 was a fatal receptor that mediated the MDP-induced A1-42
oligomer production.
Finally, the effect of siRNA NOD2 on the MDP-induced activation of p-38 MAPK and
BACE1 was assessed (Fig. 4A). As seen in Fig. 4C-4D, the SH-SY5Y
cells transfected with siRNA, exhibited decreased expression of p-p38 MAPK and
BACE1 after treatment with MDP. Results from qRT-PCR (Fig. 4J) showed that
siRNA NOD2 repressed the mRNA level of BACE1 that was induced by MDP. Therefore,
it was suggested that NOD2 mediated the MDP-induced A1-42 oligomer
production via the p-p38 MAPK/BACE1 pathway in the SH-SY5Y cells.
Fig. 4.
siRNA NOD2 inhibited the MDP-induced upregulation of
p-p38 MAPK, BACE1, and A1-42 oligomer in the SH-SY5Y cells. (A) The
expressions of NOD2, p-p38 MAPK, p-38 MAPK, BACE1, A1-42 monomer, and
A1-42 oligomer were determined by western blot. The mRNA level of NOD2
and BACE1 were shown in (I) and (J). (G) A1-42 location within the
cytoplasm of the SH-SY5Y cells was induced by MDP (10 g/ml) and was
repressed by siRNA NOD2 (50 nM). A1-42 is shown in green and DAPI in
blue color. Bar = 10 m. (B-F, H) are the corresponding bar graphs showing
quantification of (A) and (G), respectively. Results are expressed as the mean
SEM from at least three separate experiments.Note. versus control: P 0.05, versus control:
P 0.01, versus control: P 0.001, versus
MDP group: P 0.05, versus MDP group: P 0.01,
versus MDP group: P 0.001.
4. Discussion
The etiology of AD is highly complex and emphasizes the primacy of the
A1-42 oligomer (De Strooper and Karran, 2016). Recent observations
demonstrated that bacteria could invade the central nervous system (CNS) and
drive the formation of senile plaques (SPs) that are considered as the underlying
cause of AD (Dominy et al., 2019; Kumar et al., 2016). The
amyloid beta-precursor protein (APP) and A might occur in
bacterial biofilms. Meanwhile, SPs were reported to contain elements of biofilm
constituents, revealing that the co-localization of biofilms with A is a
signature finding in AD (Fulop et al., 2018). Some scholars suggested that
the production and deposition of A may be related to certain critical
components in the biofilms (Allen and Morales, 2016; Miklossy, 2016). LPS,
derived from the gram-negative bacterial biofilm, could have the expression of
A in the brains of ICR mice (Choi et al., 2017; Kim et al., 2017).
We expected to seek an extensively representative component to elucidate the
molecular mechanism of bacteria in promoting A production. MDP is an
immunoreactive derivative of peptidoglycan that is commonly found in all bacteria
(Park et al., 2017); it plays a vital role in the amplification of
inflammation in neurodegenerative diseases (Cheng et al., 2018). Therefore,
MDP emerged as a suitable candidate to mimic the bacteria-induced infected
microenvironment in the brain.
To test the above hypothesis, the WT mice were
first injected with MDP. Results from the western blot confirmed the role of MDP
in promoting the production of the cerebral A1-42 oligomer (Fig. 1A). To investigate the developing effects of MDP on A1-42 oligomer
production at the cellular level, the SH-SY5Y cells were further incubated with
MDP. Results from the western blot showed that MDP up-regulated the expression of
A1-42 oligomer in a dose- and time-dependent manner (Fig. 2A and
2C). It was initially determined that bacterial MDP was
the possible trigger factor that promoted A1-42 oligomer production
under in vivo and in vitro conditions. Nevertheless, the
precise mechanism remained unclear.
BACE1 is thought to initiate the amyloidogenic pathway that cleaves APP
to form the N-terminus of the A peptides (Read and Suphioglu, 2019).
Extensive research has mentioned that cerebral BACE1 is hyperactivated in AD
patients and mice (Fukumoto et al., 2004). However, sustained BACE1
inhibition could reverse the amyloid deposition, indicating that BACE1 is closely
related to the process of A production (Hu et al., 2018). Bacteria
and their active components have been reported to upregulate the expression of
BACE1 (Choi et al., 2017; Kim et al., 2017). Despite this, the relationship
between MDP and BACE1 is undefined.
It was found that the
WT mice injected with MDP exhibited a higher expression of BACE1 (Fig. 1A).
The above in vivo published result was consistent with our in
vitro result that indicated that MDP increased both the gene expression and the
mRNA level of BACE1 in a dose- and time-dependent manner in the SH-SY5Y cells
(Fig. 2A, 2C, 2E, and 2F). It was suggested that the
MDP-dependent upregulation of the expression of A1-42 oligomer might be
related to BACE1. Hence, it was feasible to seek the mechanism of MDP-induced
A1-42 oligomer production based on BACE1. Accumulating research has
proved that the p-38 MAPK plays a critical role in the regulation of BACE1 and
A in AD pathogenesis (Schnöder et al., 2016). MDP has been
reported to activate the p-38 MAPK (Chen et al., 2018; Liu et al., 2015). As
expected, the WT mice and the SH-SY5Y cells exhibited a higher expression of
p-p38 MAPK after treatment with MDP (Fig. 1A, 2A, and 2C). However,
little information is available regarding the crosstalk between the p-38 MAPK and
MDP-induced upregulation of BACE1 and A1-42 oligomer. Therefore, the
p-38 MAPK inhibitor, SB203580, was utilized to observe the role of MDP in this
process. It was noticed that the SH-SY5Y cells pretreated with SB203580 exhibited
a lower ratio of p-p38 MAPK/p-38 MAPK after treatment with MDP in comparison with
the ratio observed in the control cells (Fig. 3A-B). Meanwhile, SH-SY5Y cells
pretreated with SB203580 exhibited decreased BACE1 levels at both the gene
expression (Fig. 3A) and the mRNA levels (Fig. 3H). The next step was the
detection of the A1-42 oligomer. Results from LSCM and western blot
confirmed that SB203580 repressed the increased expression of A1-42
oligomer that was induced by MDP (Fig. 3A and 3F). It was revealed that
MDP induced the upregulation of BACE1 and A1-42 oligomer via a p-38
MAPK-dependent pathway.
Multiple studies indicate that NOD2 is a risk factor for neurodegenerative
disorders like Parkinson’s disease (PD) (Cheng et al., 2018; Ma et al., 2013)
and multiple sclerosis (MS) (White et al., 2014). Previous research has
revealed that NOD2 induces neuronal damage and cognitive dysfunction, thus
implying a pathological role of NOD2 in AD as well (Chauhan et al., 2009; Liu et al., 2015). However, less information is available about the relationship
between NOD2 and A1-42 oligomer. To investigate this aspect, the SH-SY5Y
cells were transfected with siRNA NOD2. It was shown that the MDP-induced
increase in the A1-42 oligomer level was repressed by siRNA NOD2 (Fig. 4A and 4H). This suggested that MDP might promote A1-42 oligomer
production in a NOD2-dependent manner.
Numerous studies have proved that NOD2 regulates the p-38 MAPK to amplify an
inflammatory response (Negroni et al., 2018; Zhang et al., 2015). However,
the involvement of NOD2 in MDP-induced upregulation of p-p38 MAPK remains
uncertain. It was further detected that SH-SY5Y cells transfected with siRNA NOD2
exhibited a lower expression of p-p38 MAPK after treatment with MDP (Fig. 4A). Moreover, siRNA NOD2 inhibited the MDP-induced upregulation of BACE1 at
both the gene expression and the mRNA levels (Fig. 4A and 4J). Thus, it
was demonstrated that NOD2 mediated the MDP-induced A1-42 oligomer
production via the p-p38 MAPK/BACE1-dependent pathway in the SH-SY5Y cells.
It was initially demonstrated that MDP promoted A1-42 oligomer
production via the NOD2/p-p38 MAPK/BACE1 pathway in the in vivo (mice)
and the in vitro SH-SY5Y models. These results might provide a possible
underlying mechanism to investigate bacteria-induced A1-42 oligomer
production or the amyloidogenesis in Alzheimer’s disease. However, there are some
limitations. (1) LPS has been reported to be associated with A
aggregation and neuronal toxicity (Martins, 2018). For example, the
distribution of LPS on the cell membrane and its interaction with apolipoprotein
E disorders the peripheral A metabolism and further affects the
A generation in neurodegeneration and AD (Martins, 2015).
Besides, MDP synergistically enhances the LPS-mediated biological activities
(Kitaura et al., 2018). Therefore, the role of LPS needs to be considered in
the investigation of bacteria-induced A generation in SH-SY5Y cells.
Moreover, we need to explore whether MDP plays a role in A generation
independent of LPS or synergistically with LPS in SH-SY5Y cells. (2) It is
well-known that the pathological process of A aggregation involving
excessive A production and perturbated A clearance. However,
our research focused on exploring the mechanism of A production
induced by MDP. More experiments need to determine whether MDP-induced A
precipitation is related to the perturbated A clearance. (3)
Neuroinflammation and A aggregation are the primary pathogenic
mechanisms of AD. NOD2 is one of the well-studied members of the NLRs. It has
been reported that MDP activates the human NLRP1 inflammasome and induces
interleukin-1 beta processing by NOD2 (Cui et al., 2014; Hsu et al., 2008; Pan et al., 2007). Therefore, it is necessary to explore if MDP mediates
neuroinflammation in AD by NOD2. Thus, in our following study, we would like to
further investigate the role of NOD2 in A clearance induced by MDP to
provide a precise mechanism for the bacterial promotion of the deposition of
A.
Author contributions
Ya-Ming Li and Chun-Yan Zhang designed the research study. Yan-Jie Chen performed the research. Yuan-Jin Chan provided help and advice on the western blot experiments. Yan-Jie Chen analyzed the data. Yan-Jie Chen and Wen-Jing Chen wrote the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The Animal Ethics Committee approved this study of the Department of Laboratory
Animal Science of Fudan University (Approval No: 201902006S).
Acknowledgments
Thanks to all the peer reviewers and editors for their opinions and suggestions.
Conflict of Interest
The authors declare no conflict of interest regarding the publication of this
paper.